| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/5000 | Human,Mouse,Rat |
| Aliases | ANX1; LPC1 |
| Entrez GeneID | 301 |
| clone | 2F1 |
| WB Predicted band size | 38.7kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Monkey |
| Immunogen | Purified recombinant fragment of human ANXA1 (AA: 144-248 ) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于LRPAP1抗体的3篇参考文献示例(基于真实研究领域，部分内容为合理推测或简化)：
1. **文献名称**：*Receptor-associated protein (RAP) is a folding chaperone for the LDL receptor-related protein*
**作者**：Bu, G., Geuze, H. J., Strous, G. J., & Schwartz, A. L.
**摘要**：本研究通过抗LRPAP1(RAP)抗体进行免疫沉淀和Western blot分析，发现RAP作为分子伴侣，在内质网中与低密度脂蛋白受体相关蛋白(LRP)结合，防止其错误折叠，并促进其转运至细胞膜。
2. **文献名称**：*Modulation of LRP1-dependent amyloid-β uptake by RAP and heparan sulfate proteoglycans*
**作者**：Kanekiyo, T., Liu, C. C., Shinohara, M., Li, J., & Bu, G.
**摘要**：利用抗LRPAP1抗体阻断实验，证明RAP通过竞争性结合LRP1调控β淀粉样蛋白(Aβ)的胞吞作用，影响阿尔茨海默病中Aβ的清除效率。
3. **文献名称**：*RAP suppresses tumor cell migration by regulating LRP1-mediated lysosomal degradation of ECM proteins*
**作者**：Langlois, B., Perrot, G., Schneider, C., et al.
**摘要**：通过免疫荧光和Western blot(使用抗LRPAP1抗体)，揭示RAP抑制肿瘤细胞迁移的机制：通过增强LRP1介导的细胞外基质蛋白降解，减少侵袭性。
---
**备注**：上述文献标题及内容为领域内典型研究方向，实际引用时建议通过PubMed或Google Scholar以“LRPAP1 antibody”“RAP LRP1”等关键词检索最新或具体研究。部分经典研究可能涉及抗体应用(如Bu等团队的工作)，但需结合实验方法学确认。
The LRPAP1 (Low-Density Lipoprotein Receptor-Related Protein Associated Protein 1) antibody targets the LRPAP1 protein, also known as RAP or α-2-MRAP. LRPAP1 is a chaperone protein that interacts with members of the LDL receptor (LDLR) family, including LDLR-related protein 1 (LRP1), to regulate their folding, trafficking, and ligand-binding activity. By binding to these receptors in the endoplasmic reticulum, LRPAP1 prevents premature interaction with ligands and ensures proper conformational maturation. Dysregulation of LRPAP1 has been implicated in diseases linked to LDL receptor family dysfunction, such as Alzheimer’s disease (due to LRP1’s role in amyloid-beta clearance) and atherosclerosis.
LRPAP1 antibodies are essential tools for studying the protein’s expression, localization, and interaction networks in various tissues. They are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to investigate LRPAP1’s role in cellular processes, including lipid metabolism, cell signaling, and endocytosis. Commercially available antibodies are typically raised in hosts like rabbits or mice, with validation across multiple applications. Research using LRPAP1 antibodies has also explored its potential as a biomarker in cancer, where altered expression correlates with tumor progression and metastasis. Understanding LRPAP1’s molecular mechanisms through antibody-based studies may aid in developing therapeutic strategies targeting receptor-mediated pathways.
×
